Aardvark Therapeutics (AARD) EBT (2024 - 2026)
Aardvark Therapeutics (AARD) posted EBT of -$21.6 million for Q1 2026, down 22.73% sequentially from -$17.6 million in Q4 2025, and down 132.09% YoY from $67.2 million in Q1 2025.
Aardvark Therapeutics (AARD) EBT (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported EBT for 3 years, with the latest figure at -$21.6 million in Q1 2026.
- Quarterly EBT fell 132.09% year-over-year to -$21.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$69.9 million (down 127.08% YoY) and the FY2025 annual result came in at -$69.9 million, down 80.24% from the prior year.
- EBT fell to -$21.6 million in Q1 2026 per AARD's latest filing, from -$17.6 million in the prior quarter.
- Over five years, EBT peaked at -$2.1 million in Q1 2024 and troughed at -$21.6 million in Q1 2026.
- A 3-year average of -$11.4 million and a median of -$11.9 million in 2024 frame the typical range for EBT.
- The widest YoY moves for EBT: up 47.62% in 2025, down 349.52% in 2025.
- Over 3 years, EBT stood at -$11.9 million in 2024, then slumped by 47.62% to -$17.6 million in 2025, then declined by 22.73% to -$21.6 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$21.6 million, -$17.6 million, and -$16.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Aardvark Therapeutics | 127.36 Mn | 53.44 Mn | - | -14.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.39 Mn |
| Mar 31, 2026 | -21.58 Mn |
| Dec 31, 2025 | -17.58 Mn |
| Sep 30, 2025 | -16.35 Mn |
| Jun 30, 2025 | -14.38 Mn |
| Mar 31, 2025 | -9.30 Mn |
| Dec 31, 2024 | -11.91 Mn |
| Sep 30, 2024 | -4.09 Mn |
| Jun 30, 2024 | -5.48 Mn |
| Mar 31, 2024 | -2.07 Mn |